395 results
8-K
EX-99.2
EBS
Emergent Biosolutions Inc
1 May 24
Emergent Biosolutions Reports First Quarter 2024 Financial Results
4:44pm
define Adjusted EBITDA, which is a non-GAAP financial measure, as consolidated net income (loss) before income tax provision (benefit), interest expense … — 1.1 SG&A Other income (expense), net items 3.1 — Other Income (Expense) Tax effect (4.2) (6.4) Total adjustments: $ 22.1 $ 22.7 Adjusted net income
8-K
EX-99.1
EBS
Emergent Biosolutions Inc
1 May 24
Emergent Biosolutions Reports First Quarter 2024 Financial Results
4:44pm
underlying trends.
We define Adjusted EBITDA, which is a non-GAAP financial measure, as consolidated net income (loss) before income tax provision (benefit … tax liability
Other liabilities
Total liabilities
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 15.0 shares authorized, no shares
8-K
EX-10.1
EBS
Emergent Biosolutions Inc
26 Apr 24
Departure of Directors or Certain Officers
4:30pm
OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT. 10. Tax. Amounts payable under the KERP Agreement and KERP Amendment are subject to withholding
8-K
EX-10.1
c9ji512dju fsbkq6m
6 Mar 24
Emergent Biosolutions Reports Fourth Quarter 2023 Financial Results
4:15pm
8-K
EX-99.2
gmu4 haxzg0uh71r
6 Mar 24
Emergent Biosolutions Reports Fourth Quarter 2023 Financial Results
4:15pm
8-K
EX-99.1
btm a48lc36yc
6 Mar 24
Emergent Biosolutions Reports Fourth Quarter 2023 Financial Results
4:15pm
8-K
EX-10.1
2nx3bys6tuq
21 Feb 24
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
7:25am
8-K
EX-99.2
gbrsx
9 Jan 24
Regulation FD Disclosure
8:40am
8-K
EX-99.1
0zerffvudc09me hvn
24 Nov 23
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
7:17am
8-K
89yvufh82cx 1snqabyc
16 Nov 23
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:11pm
NT 10-Q
un4h2d 9bmtvn
9 Nov 23
Notice of late quarterly filing
4:22pm